• LAST PRICE
    394.0400
  • TODAY'S CHANGE (%)
    Trending Down-4.5500 (-1.1415%)
  • Bid / Lots
    394.3000/ 1
  • Ask / Lots
    394.7700/ 1
  • Open / Previous Close
    397.6100 / 398.5900
  • Day Range
    Low 394.0400
    High 397.7900
  • 52 Week Range
    Low 327.7250
    High 550.7600
  • Volume
    13,906
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 398.63
TimeVolumeARGX
09:32 ET901397.11
09:34 ET500394.635
09:36 ET680395.93
09:38 ET200395.655
09:39 ET300395.14
09:41 ET300395.91
09:43 ET400395.71
09:45 ET300395.465
09:48 ET100395.4
09:52 ET100395.695
09:54 ET100395.9
09:56 ET200395.74
09:59 ET300394.96
10:01 ET200394.04
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesARGX
argenx SE
23.6B
-76.6x
---
United StatesALNY
Alnylam Pharmaceuticals Inc
19.4B
-42.5x
---
United StatesSRPT
Sarepta Therapeutics Inc
12.2B
-21.0x
---
United StatesTECH
Bio-Techne Corp
10.9B
50.5x
+23.61%
United StatesNBIX
Neurocrine Biosciences Inc
13.7B
56.5x
+62.04%
United StatesBMRN
Biomarin Pharmaceutical Inc
16.7B
100.5x
---
As of 2024-03-28

Company Information

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Contact Information

Headquarters
Laarderhoogtweg 25AMSTERDAM, Netherlands 1101 EB
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Peter Verhaeghe
Chief Executive Officer, Co-Founder, Executive Director
Tim Van Hauwermeiren
Chief Financial Officer
Karl Gubitz
Chief Operating Officer
Karen Massey
Chief Scientific Officer
Peter Ulrichts

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$23.6B
Revenue (TTM)
$1.2B
Shares Outstanding
59.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.65
EPS
$-5.14
Book Value
$69.22
P/E Ratio
-76.6x
Price/Sales (TTM)
19.3
Price/Cash Flow (TTM)
---
Operating Margin
-34.66%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.